McMaster Immunology Research Centre, Department of Pathology and Molecular Medicine, McMaster University, Michael G. DeGroote Center for Learning and Discovery, Hamilton, Ontario, Canada.
Microb Pathog. 2013 May;58:45-54. doi: 10.1016/j.micpath.2012.11.001. Epub 2012 Nov 15.
HSV-2 is one of the most prevalent sexually transmitted infections that result in significant morbidity and financial burden on health systems around the world. Recurrent and asymptomatic re-activation accompanied by viral shedding is common among sero-positive individuals, leading to relatively high efficiency of transmission. Prophylactic HSV-2 vaccines are the best and cheapest option to address the problems associated with HSV-2 infections globally. However, despite persistent efforts, the search for an efficacious vaccine for HSV-2 remains elusive. In this review, the current state of HSV-2 vaccines and the outcome of past human trials are examined. Furthermore, we discuss the evidence and strategies from experimental mouse models that have been successful in inducing protective immunity in the genital tract against HSV-2, following immunization. Future vaccination strategies that focus on induction of robust mucosal immunity in the genital tract may hold the key for a successful vaccine against HSV-2.
单纯疱疹病毒 2 型（HSV-2）是一种最常见的性传播感染，它会导致全世界的卫生系统出现重大的发病率和财政负担。在血清阳性个体中，复发和无症状再激活伴随着病毒脱落是很常见的，这导致了相对较高的传播效率。预防性 HSV-2 疫苗是解决全球 HSV-2 感染相关问题的最佳和最便宜的选择。然而，尽管持续努力，针对 HSV-2 的有效疫苗仍难以找到。在这篇综述中，我们检查了 HSV-2 疫苗的现状和过去人类试验的结果。此外，我们还讨论了实验性小鼠模型中的证据和策略，这些策略在免疫接种后成功地诱导了针对生殖器部位 HSV-2 的保护性免疫。未来专注于诱导生殖道内强大黏膜免疫的疫苗接种策略可能是成功预防 HSV-2 的关键。
